Article
Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas.
Molecules (Basel, Switzerland) - 4 Dec 2021
Hirata Amanda S, Rezende-Teixeira Paula, Machado-Neto João Agostinho, Jimenez Paula C, Clair James J La, Fenical William, Costa-Lotufo Leticia V
Abstract excerpt
Isolated from the marine bacteria Serinicoccus sp., seriniquinone (SQ1) has been characterized by its selective activity in melanoma cell lines marked by its modulation of human dermcidin and induction of autophagy and apoptosis. While an active lead, the lack of solubility of SQ1 in both organic and aqueous media has complicated its preclinical evaluation. In response, our team turned its effort to explore...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
